96.11MMarket Cap-676P/E (TTM)
0.810High0.771Low291.65KVolume0.810Open0.782Pre Close230.08KTurnover0.24%Turnover RatioLossP/E (Static)124.68MShares1.95052wk High-0.73P/B94.87MFloat Cap0.61752wk Low--Dividend TTM123.08MShs Float49.005Historical High--Div YieldTTM5.05%Amplitude0.617Historical Low0.788Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet